{
    "address1": "One Amgen Center Drive",
    "city": "Thousand Oaks",
    "state": "CA",
    "zip": "91320-1799",
    "country": "United States",
    "phone": "805 447 1000",
    "fax": "805 447 1010",
    "website": "https://www.amgen.com",
    "industry": "Drug Manufacturers\u2014General",
    "sector": "Healthcare",
    "longBusinessSummary": "Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. It focuses on inflammation, oncology/hematology, bone health, cardiovascular disease, nephrology, and neuroscience areas. The company's products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Neulasta that reduces the chance of infection due a low white blood cell count in patients cancer; Prolia to treat postmenopausal women with osteoporosis; Xgeva for skeletal-related events prevention; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Beh\u00e7et's disease; Aranesp to treat a lower-than-normal number of red blood cells and anemia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; and Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization. It also markets Nplate, Vectibix, MVASI, Parsabiv, EPOGEN, KANJINTI, BLINCYTO, Aimovig, EVENITY, AMGEVITATM, Sensipar/Mimpara, NEUPOGEN, IMLYGIC, Corlanor, and AVSOLA. Amgen Inc. serves healthcare providers, including physicians or their clinics, dialysis centers, hospitals, and pharmacies. It distributes its products through pharmaceutical wholesale distributors, as well as direct-to-consumer channels. It has collaboration agreements with Novartis Pharma AG; UCB; Bayer HealthCare LLC; BeiGene, Ltd.; Eli Lilly and Company; Datos Health; and Verastem, Inc. to evaluate VS-6766 in combination with lumakrastm (Sotorasib) in patients with KRAS G12C-mutant non-small cell lung cancer. It has an agreement with Kyowa Kirin Co., Ltd. to jointly develop and commercialize KHK4083, a Phase 3-ready anti-OX40 fully human monoclonal antibody for the treatment of atopic dermatitis and other autoimmune diseases; and research and development collaboration with Neumora Therapeutics, Inc. and Plexium, Inc. Amgen Inc. was incorporated in 1980 and is headquartered in Thousand Oaks, California.",
    "fullTimeEmployees": 25200,
    "companyOfficers": [
        {
            "maxAge": 1,
            "name": "Mr. Robert A. Bradway",
            "age": 59,
            "title": "Chairman, CEO & Pres",
            "yearBorn": 1963,
            "fiscalYear": 2022,
            "totalPay": 5487475,
            "exercisedValue": 0,
            "unexercisedValue": 43693576
        },
        {
            "maxAge": 1,
            "name": "Mr. Peter H. Griffith",
            "age": 63,
            "title": "Exec. VP & CFO",
            "yearBorn": 1959,
            "fiscalYear": 2022,
            "totalPay": 2574004,
            "exercisedValue": 0,
            "unexercisedValue": 245771
        },
        {
            "maxAge": 1,
            "name": "Mr. Esteban  Santos",
            "age": 54,
            "title": "Exec. VP of Operations",
            "yearBorn": 1968,
            "fiscalYear": 2022,
            "totalPay": 2521941,
            "exercisedValue": 0,
            "unexercisedValue": 8232750
        },
        {
            "maxAge": 1,
            "name": "Dr. David M. Reese M.D.",
            "age": 59,
            "title": "Exec. VP of R&D",
            "yearBorn": 1963,
            "fiscalYear": 2022,
            "totalPay": 2833393,
            "exercisedValue": 0,
            "unexercisedValue": 4932458
        },
        {
            "maxAge": 1,
            "name": "Mr. Murdo  Gordon",
            "age": 55,
            "title": "Exec. VP of Global Commercial Operations",
            "yearBorn": 1967,
            "fiscalYear": 2022,
            "totalPay": 2717562,
            "exercisedValue": 0,
            "unexercisedValue": 2469817
        },
        {
            "maxAge": 1,
            "name": "Mr. Matthew C. Busch",
            "age": 48,
            "title": "Chief Accounting Officer & VP of Fin.",
            "yearBorn": 1974,
            "exercisedValue": 0,
            "unexercisedValue": 0
        },
        {
            "maxAge": 1,
            "name": "Mr. Mike  Zahigian",
            "title": "Sr. VP & Chief Information Officer",
            "exercisedValue": 0,
            "unexercisedValue": 0
        },
        {
            "maxAge": 1,
            "name": "Mr. Arvind  Sood",
            "title": "VP of Investor Relations",
            "exercisedValue": 0,
            "unexercisedValue": 0
        },
        {
            "maxAge": 1,
            "name": "Mr. Jonathan P. Graham",
            "age": 61,
            "title": "Exec. VP, Gen. Counsel & Sec.",
            "yearBorn": 1961,
            "fiscalYear": 2019,
            "exercisedValue": 0,
            "unexercisedValue": 0
        },
        {
            "maxAge": 1,
            "name": "Ms. Nancy A. Grygiel",
            "age": 54,
            "title": "Sr. VP of Worldwide Compliance & Bus. Ethics and Chief Compliance Officer",
            "yearBorn": 1968,
            "exercisedValue": 0,
            "unexercisedValue": 0
        }
    ],
    "auditRisk": 4,
    "boardRisk": 9,
    "compensationRisk": 3,
    "shareHolderRightsRisk": 1,
    "overallRisk": 3,
    "governanceEpochDate": 1693526400,
    "compensationAsOfEpochDate": 1672444800,
    "maxAge": 86400,
    "priceHint": 2,
    "previousClose": 254.39,
    "open": 255.75,
    "dayLow": 255.08,
    "dayHigh": 260.34,
    "regularMarketPreviousClose": 254.39,
    "regularMarketOpen": 255.75,
    "regularMarketDayLow": 255.08,
    "regularMarketDayHigh": 260.34,
    "dividendRate": 8.52,
    "dividendYield": 0.0328,
    "exDividendDate": 1692230400,
    "payoutRatio": 0.5485,
    "fiveYearAvgDividendYield": 2.93,
    "beta": 0.613762,
    "trailingPE": 17.481806,
    "forwardPE": 13.719196,
    "volume": 2449115,
    "regularMarketVolume": 2449115,
    "averageVolume": 2551730,
    "averageVolume10days": 1920330,
    "averageDailyVolume10Day": 1920330,
    "bid": 0.0,
    "ask": 0.0,
    "bidSize": 900,
    "askSize": 1200,
    "marketCap": 138769367040,
    "fiftyTwoWeekLow": 211.71,
    "fiftyTwoWeekHigh": 296.67,
    "priceToSalesTrailing12Months": 5.220426,
    "fiftyDayAverage": 243.6506,
    "twoHundredDayAverage": 245.29105,
    "trailingAnnualDividendRate": 8.14,
    "trailingAnnualDividendYield": 0.031998113,
    "currency": "USD",
    "enterpriseValue": 166065405952,
    "profitMargins": 0.30017,
    "floatShares": 533756492,
    "sharesOutstanding": 534900992,
    "sharesShort": 7027270,
    "sharesShortPriorMonth": 7176404,
    "sharesShortPreviousMonthDate": 1689292800,
    "dateShortInterest": 1692057600,
    "sharesPercentSharesOut": 0.013099999,
    "heldPercentInsiders": 0.0023700001,
    "heldPercentInstitutions": 0.79324996,
    "shortRatio": 2.43,
    "shortPercentOfFloat": 0.013200001,
    "bookValue": 12.677,
    "priceToBook": 20.46462,
    "lastFiscalYearEnd": 1672444800,
    "nextFiscalYearEnd": 1703980800,
    "mostRecentQuarter": 1688083200,
    "earningsQuarterlyGrowth": 0.047,
    "netIncomeToCommon": 7978999808,
    "trailingEps": 14.84,
    "forwardEps": 18.91,
    "pegRatio": 8.24,
    "lastSplitFactor": "2:1",
    "lastSplitDate": 943228800,
    "enterpriseToRevenue": 6.247,
    "enterpriseToEbitda": 12.066,
    "exchange": "NMS",
    "quoteType": "EQUITY",
    "symbol": "AMGN",
    "underlyingSymbol": "AMGN",
    "shortName": "Amgen Inc.",
    "longName": "Amgen Inc.",
    "firstTradeDateEpochUtc": 424704600,
    "timeZoneFullName": "America/New_York",
    "timeZoneShortName": "EDT",
    "gmtOffSetMilliseconds": -14400000,
    "currentPrice": 259.43,
    "targetHighPrice": 320.0,
    "targetLowPrice": 185.0,
    "targetMeanPrice": 258.71,
    "targetMedianPrice": 264.0,
    "recommendationMean": 2.6,
    "recommendationKey": "hold",
    "numberOfAnalystOpinions": 21,
    "totalCash": 34247999488,
    "totalCashPerShare": 64.027,
    "ebitda": 13763000320,
    "totalDebt": 61544001536,
    "quickRatio": 2.344,
    "currentRatio": 2.771,
    "totalRevenue": 26581999616,
    "debtToEquity": 907.595,
    "revenuePerShare": 49.732,
    "returnOnAssets": 0.08541001,
    "returnOnEquity": 1.73457,
    "grossProfits": 19917000000,
    "freeCashflow": 10054124544,
    "operatingCashflow": 10800000000,
    "earningsGrowth": 0.049,
    "revenueGrowth": 0.059,
    "grossMargins": 0.74294996,
    "ebitdaMargins": 0.51776004,
    "operatingMargins": 0.38443002,
    "financialCurrency": "USD",
    "trailingPegRatio": 1.9114,
    "parent_etfs": [
        "AGNG"
    ]
}